Paul Tudor Jones Igm Biosciences, Inc. Transaction History
Tudor Investment Corp Et Al
- $19.2 Billion
- Q2 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 14,537 shares of IGMS stock, worth $247,129. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,537Holding current value
$247,129% of portfolio
0.0%Shares
8 transactions
Others Institutions Holding IGMS
# of Institutions
87Shares Held
21.4MCall Options Held
39.5KPut Options Held
16.5K-
Baker Bros. Advisors LP New York, NY4.09MShares$69.5 Million0.37% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.08MShares$69.3 Million0.0% of portfolio
-
Artal Group S.A. Luxembourg, N43.33MShares$56.6 Million1.45% of portfolio
-
Redmile Group, LLC San Francisco, CA3.07MShares$52.2 Million1.38% of portfolio
-
Goldman Sachs Group Inc New York, NY1.33MShares$22.7 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $492M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...